On May 12, 2022, the Supreme Court of Canada dismissed an application by Canada RNA Biochemical (C-RNA) for leave to appeal (Docket No. 39994) a decision of the Federal Court of Appeal relating to the refusal of a Natural Health Product (NHP) licence for C-RNA's oral lumbrokinase capsules (BOLUOKE).
As previously reported, the Federal Court of Appeal did not find any reviewable error in the decision of the Minister of Health (Minister) to refuse granting an NHP licence for BOLUOKE or in the Federal Court's reasoning in dismissing C-RNA's application for judicial review of the Minister's decision.
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.